BE1116 + FFP
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Conditions
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Trial Timeline
Sep 15, 2025 → Dec 17, 2026
NCT ID
NCT07094087About BE1116 + FFP
BE1116 + FFP is a phase 3 stage product being developed by CSL for Complex Cardiovascular Surgery With Cardiopulmonary Bypass. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07094087. Target conditions include Complex Cardiovascular Surgery With Cardiopulmonary Bypass.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07094087 | Phase 3 | Recruiting |
Competing Products
20 competing products in Complex Cardiovascular Surgery With Cardiopulmonary Bypass
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zonisamide | Eisai | Phase 3 | 77 |
| Eslicarbazepine acetate + Eslicarbazepine acetate | Sumitomo Pharma | Phase 3 | 77 |
| Everolimus (RAD001) + Everolimus Placebo | Novartis | Phase 3 | 77 |
| Zoledronic acid + Placebo | Novartis | Phase 2 | 52 |
| RAD001 + Placebo | Novartis | Phase 2 | 52 |
| RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) | Novartis | Phase 3 | 77 |
| everolimus | Novartis | Phase 3 | 77 |
| ranolazine | Gilead Sciences | Phase 2 | 51 |
| clarithromycin, rifabutin | Pfizer | Approved | 84 |
| Pregabalin + Pregabalin | Pfizer | Approved | 84 |
| Pregabalin | Pfizer | Pre-clinical | 22 |
| Azithromycin | Pfizer | Approved | 84 |
| Azithromycin + Rifabutin/rifampin | Pfizer | Approved | 84 |
| Stavudine | Bristol Myers Squibb | Phase 3 | 76 |
| Zidovudine + Didanosine | Bristol Myers Squibb | Phase 2 | 51 |
| Haemocomplettan® P + Human albumin (Placebo) | CSL | Phase 2/3 | 64 |
| CSL730 + Placebo | CSL | Phase 1 | 32 |
| vigabatrin | Lundbeck | Approved | 82 |
| Sabril | Lundbeck | Approved | 82 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |